Investors had been concerned about potential global tariffs as biopharma has significant manufacturing operations in countries like Ireland, Germany and Switzerland. U.S. biopharma firms ...

FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach ...

The Wall Street Journal first reported news of Marks’ resignation. Both HHS and FDA did not respond to multiple requests by BioPharma Dive for comment. “I had the chance to work closely with [Marks],” ...

“Tariffs could force biopharma companies to alter both transfer pricing strategies and global supply chain activities to reduce the US ‘landing price’ of imported product,” the analysts wrote.

The company is focused on its alcohol metabolism and multiple sclerosis treatments. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) said Friday it’s made some inroads with its financials ...

Dreams and fears define “Tel'aran'rhiod,” which continues The Wheel of Time’s strong third season by pushing characters to confront their weaknesses and limitations. It demonstrates how much ...

Over the past decades, roboticists have introduced a wide range of systems that can move in various complex environments, including different terrains, on the ground, in the air, and even in water. To ...

With its active pharmaceutical ingredient (API) facility “in a state of disrepair,” manufacturer Aspen Biopharma Labs’ operations have ground to a halt in the U.S., according to a recent FDA ...

The Trump ad­min­is­tra­tion’s threat­ened tar­iffs on Eu­rope would be painful for the biotech in­dus­try, ac­cord­ing to da­ta from a sur­vey con­duct­ed by the in­dus­try’s ...